RxDoctor Payments Data

John Bertini, DO

Internal Medicine · Endwell, NYNPI 1225267982

Payments from drug & device makers

$1,541in general payments, 2019–2025

Across 78 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$476
  • Novo Nordisk$248
  • GSK$181
  • Abbott$170
  • Pfizer$76
  • Exact Sciences$62
  • plus $327 from 8 others

What the payments were for

  • Food & beverage$1,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,541 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$104,648
Medicare patients
351
Services billed
1,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$411,397
OzempicSemaglutide108$202,648
JardianceEmpagliflozin97$142,643
XareltoRivaroxaban92$129,775
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$91,830
TrulicityDulaglutide29$71,400
MounjaroTirzepatide55$62,850
RybelsusSemaglutide25$52,431
JanuviaSitagliptin Phosphate30$49,069
FarxigaDapagliflozin Propanediol31$47,723
LinzessLinaclotide31$32,274
ArexvyRsvpref3 Antigen/As01e/Pf99$30,925
XolairOmalizumab13$29,887
EntrestoSacubitril/Valsartan24$28,469
Repatha SureclickEvolocumab16$20,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$76$420,698309 claims
Novo NordiskOzempic, Rybelsus$248$255,079133 claims
GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix, Arnuity Ellipta$181$160,640261 claims
AstraZenecaFarxiga, Symbicort, Nexium, Brilinta$58$76,18878 claims
AbbVieLinzess$476$32,27431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Endwell

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →